We are live on ! Find out more
FCMI

Foresite Capital Management III Portfolio holdings

AUM $37.9M
1-Year Est. Return 6.87%
This Fund
S&P 500
This Quarter Est. Return
+1.61%
1 Year Est. Return
-6.87%
3 Year Est. Return
+444.07%
5 Year Est. Return
+547.28%
10 Year Est. Return
–
AUM
$453M
AUM Growth
-$11.2M
Cap. Flow
+$610K
Cap. Flow %
0.13%
Top 10 Hldgs %
80.58%
Holding
26
New
2
Increased
2
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$13.7M
2
PACB icon
Pacific Biosciences
PACB
+$4.87M
3
IMMU
Immunomedics Inc
IMMU
+$3.55M
4
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$1.71M

Top Sells

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$4.19M
2
BPMC
Blueprint Medicines
BPMC
+$3.48M
3
AKAO
Achaogen Inc
AKAO
+$3.02M
4
AIMT
Aimmune Therapeutics
AIMT
+$1.41M
5
XLRN
Acceleron Pharma
XLRN
+$1.37M

Sector Composition

Rank Sector Weight
1 Healthcare 57.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AERI
1
DELISTED
Aerie Pharmaceuticals
AERI
$105M 23.2%
1,708,046
– –
IMMU
2
DELISTED
Immunomedics Inc
IMMU
$56.1M 12.37%
2,691,729
+150,000
+6% +$3.55M
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$49M 10.81%
2,942,130
– –
RCUS icon
4
Arcus Biosciences
RCUS
$3.36B
$48M 10.6%
3,445,461
– –
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$24.3M 5.36%
372,300
-20,489
-5% -$1.2M
AIMT
6
DELISTED
Aimmune Therapeutics
AIMT
$21.9M 4.82%
801,240
-49,973
-6% -$1.41M
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$17.3M 3.82%
1,562,040
– –
BPMC
8
DELISTED
Blueprint Medicines
BPMC
$15.6M 3.44%
200,000
-50,000
-20% -$3.48M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$14.4M 3.17%
250,863
-27,890
-10% -$1.37M
ASND icon
10
Ascendis Pharma A/S
ASND
$16.4B
$13.6M 3%
191,588
– –
REPL icon
11
Replimune Group
REPL
$526M
$12.6M 2.77%
+779,656
New +$13.7M
BOLD
12
DELISTED
Audentes Therapeutics, Inc
BOLD
$12.5M 2.75%
315,331
– –
SLDB icon
13
Solid Biosciences
SLDB
$766M
$11.2M 2.48%
15,859
-6,667
-30% -$4.19M
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$9.73M 2.15%
917,715
-22,970
-2% -$262K
AKAO
15
DELISTED
Achaogen Inc
AKAO
$9.47M 2.09%
2,374,418
-500,000
-17% -$3.02M
VRNA
16
DELISTED
Verona Pharma
VRNA
$6.27M 1.38%
500,883
-1,942
-0.4% -$25.1K
PACB icon
17
Pacific Biosciences
PACB
$426M
$6.14M 1.35%
+1,135,000
New +$4.87M
ACRS icon
18
Aclaris Therapeutics
ACRS
$744M
$4.54M 1%
312,368
– –
SGMO
19
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$4.5M 0.99%
265,605
– –
BHVN
20
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.97M 0.88%
105,706
– –
WVE icon
21
Wave Life Sciences
WVE
$1.13B
$2.5M 0.55%
50,000
-25,000
-33% -$1.13M
FBRX icon
22
Forte Biosciences
FBRX
$1.57B
$2.32M 0.51%
396
– –
BDSI
23
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.76M 0.39%
629,656
+610,156
+3,129% +$1.71M
ARDX icon
24
Ardelyx
ARDX
$1.25B
$567K 0.13%
130,304
– –
IMMU
25
CALL
DELISTED
Immunomedics Inc
IMMU
– –
-150,000
Closed -$3.55M
1
2

Similar funds

PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return
HLC
Hunt Lane Capital New York $39.6M AUM 58.74% 1-Year Est. Return
KXA
KPCB XV Associates Menlo Park, California $35.8M AUM 57.59% 1-Year Est. Return

Foresite Capital Management III's Q3 2018 Portfolio in Review

As of Q3 2018, Foresite Capital Management III held 26 positions worth $453M, down 2.4% from $464M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Foresite Capital Management III's Q3 2018 filing shows 2 new, 2 increased, 9 reduced and 2 closed positions. Its largest new stake was Replimune Group: 779,656 shares worth $12.6M. The largest sale was Solid Biosciences, an estimated $4.19M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 50% a quarter earlier.

  • Foresite Capital Management III's largest Q3 2018 buy was Replimune Group: 779,656 shares worth $12.6M.
  • Foresite Capital Management III added most to Immunomedics Inc in Q3 2018, an estimated $3.55M increase.
  • Foresite Capital Management III's biggest Q3 2018 reduction was Solid Biosciences, cutting an estimated $4.19M.
  • Foresite Capital Management III's ten largest holdings make up 81% of its $453M portfolio in Q3 2018.
  • Foresite Capital Management III opened 2 new positions and closed 2 in Q3 2018.
  • Foresite Capital Management III's portfolio value fell 2.4% quarter-over-quarter to $453M.

Based on Foresite Capital Management III's 13F filing for Q3 2018, filed 13 Nov 2018.